Ethical, economic, health system and person factors in the introduction of screening and high-priced medicines for NCDs: The example of Teplizumab for type 1 diabetes

Although screening for type 1 diabetes has been available for quite some time, until recently no therapeutic solutions were available for people identified at risk of developing this condition. The advent of Teplizumab marks a milestone for type 1 diabetes, however different factors need to be explored in order to develop appropriate responses as we transition from research settings for screening and the use of Teplizumab to implementation within health systems.

During the workshop a variety of issues were explored. First and foremost, the issue of screening and type 1 diabetes in the context of now having a disease modifying medicine. The workshop participants also explored the pros and cons of screening and Teplizumab and identified cross-cutting themes that need to be addressed when thinking about its introduction.

Type 1 diabetes screening: need for ethical, equity, and health systems perspective, Beran, David et al. The Lancet Diabetes & Endocrinology, Volume 13, Issue 3, 175 - 176